The European Commission concludes exploratory talks with Valneva to secure a new potential vaccine
On 12 January, the Commission concluded exploratory talks with the pharmaceutical company Valneva with a view to purchasing its potential vaccine against COVID-19. The envisaged contract would enable EU countries to initially purchase up to 30 million doses in total, with the option to purchase a further 30 million.
Securing doses of future vaccines
The European Commission is working closely with pharmaceutical companies and the European Medicines Agency to ensure that a safe and effective vaccine becomes available as soon as possible. As with any vaccine, they will go through rigorous scientific assessment before they are put on the market.
The European Commission has secured agreements with 6 promising vaccine developers so far, and more may come.
- 2.3 billion doses
Information about vaccination in the EU
Hear from the experts
Peter Piot, virologist
Dr Frank Ulrich Montgomery,
Hear from the people
Borislava Ananieva, transplant patient
Check the facts
Disinformation on the coronavirus is thriving. It is important that you get updated information from authoritative sources only. We suggest that you follow the advice of your public health authorities, and the websites of relevant EU and international organisations: the European Centre for Disease Control (ECDC ) and the World Health Organisation (WHO).
You can also help by not sharing unverified information that comes from dubious sources.
The EU vaccine strategy
With the EU Vaccine Strategy, the EU is supporting efforts to accelerate the development and availability of safe and effective vaccines in a timeframe between 12 and 18 months, if not earlier. Delivering on this complex task requires running clinical trials in parallel with investing in production capacity to be able to produce millions, or even billions, of doses of a successful vaccine.